Back to search

Article

A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or Nilotinib

2025-12-31

Abstract excerpt

Abstract* Background Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm driven by the BCR–ABL1 fusion gene. Tyrosine kinase inhibitors (TKIs), such as imatinib and nilotinib, have transformed CML management by significantly improving hematologic and molecular responses. However, real-world data from low- to middle-income countries, including Indonesia, remain limited. Objective This study aimed to eva...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ae9d0568-d25a-5e0e-acfa-fab1fcd187f0
DOI
10.12688/f1000research.168812.2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or NilotinibDOI 10.12688/f1000research.168812.2
A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or NilotinibSemantic proximity
Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity
Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.Semantic proximity
Real-Life Data of Patients with Chronic Myeloid Leukemia in AmazonasSemantic proximity
Early Dynamics of Chronic Myeloid Leukemia on Nilotinib Predicts Deep Molecular ResponseSemantic proximity
Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Semantic proximity
Chronic Myeloid Leukemia in Lymphoid Blast Crisis Post-Complete Remission Transforming to Therapy-Related Acute Myeloid Leukemia: A Case Report and Literature ReviewSemantic proximity
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Semantic proximity
Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity
Select a neighboring publication to make it the new centre.